Stock ANVS ANNOVIS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Delayed Nyse
Other stock markets
 04:00:02 2024-05-24 pm EDT 		5-day change 1st Jan Change
7.29 USD +2.97% Intraday chart for Annovis Bio, Inc. -12.27% -61.02%
May. 10 Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 09 Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease CI

Evolution of the average Target Price on Annovis Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

bd33cfddf1b30bca86acbe168c.mUSGf3Q2-eOjwJhqe_T4ypaHemEycRfTZPdMl112-j0.9nayMUZ9lIHJsu4lSbOrktPADFdEAE3rJrx71icYnE7_NPEGDGaeuvqIqA~21195eb51854276c2094b18a827d4f26

Analyst Recommendations on Annovis Bio, Inc.

Canaccord Genuity Cuts Price Target on Annovis Bio to $26 From $36, Maintains Buy Rating MT
Brookline Capital Downgrades Annovis Bio to Hold From Buy, $9 Price Target MT
Canaccord Genuity Initiates Annovis Bio at Buy With $36 Price Target MT
HC Wainwright Cuts Annovis Bio's Price Target to $30 From $40, Keeps Buy Rating MT
Brookline Capital Starts Annovis Bio at Buy With $35 Price Target MT
Annovis Bio, Inc. Receives Positive Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board CI
HC Wainwright Initiates Annovis Bio at Buy With $40 Price Target MT
Ladenburg Thalmann Initiates Annovis Bio at Buy with $37 Price Target MT
Maxim Group Adjusts Annovis Bio Price Target to $26 From $70, Maintains Buy Rating MT
ANNOVIS BIO : Maxim Adjusts Annovis Bio's PT to $45 from $12, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
7.29 USD
Average target price
35.25 USD
Spread / Average Target
+383.54%
High Price Target
72 USD
Spread / Highest target
+887.65%
Low Price Target
13 USD
Spread / Lowest Target
+78.33%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Annovis Bio, Inc.

Canaccord Genuity
Brookline Capital Markets
HC Wainwright
Ladenburg Thalmann
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ANVS Stock
  4. Consensus Annovis Bio, Inc.